Introduction

Rafi MARDACHTI, CEO, UNIVERSAL MEDICA GROUP

At this conference, a complete analysis of the pharmaceutical sector‘s growth dynamics will be presented (growth poles by sectorcity/hospital and by medicine profiles), in a context of reinforced standards for bringing new medicines to the market

Geraud D’ARGENLIEU, Business Development Manager, SANTEOS

In no more than three years, the emerging markets should stand at the fifth place of global sales of medicines. Based upon the Chinese example, this conference will show how pharmaceutical industry is positioned on these markets, and what are the key features that enable their penetration

Stephane SCLISON, Principal, IMS HEALTH
Alexandre WILLIAMS, Vice-President Business Development, ETHYPHARM

The current reorganisation of medical visit networks must be back up by alternative means of communication. Every year, the information technologies provide new concepts and tools for customer relationship management (e-learning, e-detailing) and for the training of the sales teams.

Jean-Pierre FAVIER, Product Manager, JANSSEN CILAG
Remi VERNIER, Sales Manager, BAYER SCHERING

Moderator : Philippe DUPERRAY, VISITE ACTUELLE

The HPST law aims firstly to create consistency between hospital and ambulatory healthcare by bringing them closer. The pharmaceutical industry must now extend itsinterlocutors target and think more on a local scale, by managing the healthcare territories with networks of local players. The workshop will attempt to clear which marketing strategies are offered to companies within the healthcare regionalisation system.

Dr. Martine AOUSTIN, Director of Regional Health Agency Languedoc-Roussillon
Fabienne PIOCH, Market Access Process Manager, BRISTOL-MYERS-SQUIBB

It is largely accepted today that the success of a treatment depends not only on the intrinsic result of the medicines but also on the care relationship and the implementation methods for the patient. Therapeutic education and training programmes strive exactly to provide answers in order to act within these differents intervention areas. The role of industry in these processes remains to be precised, given the recent evolution of the legislation. During this workshop, an overview will be done of the different intervention methods which are envisaged.

Christian SAOUT, President, CISS
Cédric GROUCHKA, Member of French National Authority for Health
David-Romain BERTHOLON, Founder, EMPATIENT

Moderator: Sebastien PRADEAU, Attorney at law

Workshop 4: Controling the stakes of outsourcing

This workshop aims to define, using concrete cases, the advantages of outsoucing in terms of cost, quality of service, risk management, functional and geographical choices.

Florence DENONAIN, Rational use of Drugs and medical information Manager, JANSSEN CILAG
Anne DEBBASCH,Medisource® Rational Use of Drugs Manager, JANSSEN CILAG

Moderator: Anne PEZET, Senior Columnist Health, USINE NOUVELLE

Champagne Cocktail by Moët & Chandon

Ruxandra DRAGHIA-AKLI , Research Manager, EUROPEAN COMMISSION
Stephane PALIES, Referent Innovation, AFSSAPS

New molecules coming from biotechnology keep arriving at a sustained pace and progressively draw again the therapeutic arsenal of prescribers. How is this market structured? Who are the main stakeholders? What are the main growth poles? How is France positioned on this market? All these questions will be discussed at this conference and answers will be proposed.

Jean-Louis DASSEUX, President, CERENIS THERAPEUTICS
Mohammed CHARKI, Partnership Director, SANOFI AVENTIS
André CHOULIKA, President, FRANCE BIOTECH

Incentive measures for innovation in Europe and in France: outcomes& prospects

France has implemented an incentive policy in favor of biotechnology, by the aid of various and complementary systems that must be well controlled by project carriers, who must put all odds in their favor to increase their chances of success. The collaboration policies within the technological parks will be discussed, as well as the incentive measures expediting collaboration between innovative SMEs and the big companies or public financing, between public and private research, etc.

Catherine BORG CAPRA, Lifesciences core, OSEO
Patrick CHAUSSEPIED, French national research agency
Bernard PAU, French Ministry of Research
Jean-Claude HILDEILFINGER, Vice President, ADEBIOTECH

Facing the waning of blockbusters, and the impoverishment of «pipeline» molecules, it is becoming essential for the healthcare industries to develop tech transfer strategies. What are the causes of tech transfer acceleration? What are the optimum conditions for efficient tech transfer? What does the future have in store for these strategies? How are knowledge transfer and tech transfer organised? What are the required facilities?... The speakers will explain their experience concerning different strategies to bring closer the different stakeholders of biotechnology.

Stéphanie LEFEBVRE, PARIS BIOTECH SANTE
Tristan ROUSSELLE, CEO, PX'THERAPEUTICS
Florence GHRENASSIA, Tech Transfer office manager, APHP-DIRC Ile de France

Moderator: Jean DEREGNAUCOURT, INSTITUT PASTEUR

Innovation Grant : Presentation of the finalist projects (part 1)

The «atomised» and multipolar biotechnology sector is made up of different protégonists, public, private, institutional, associative… This workshop is aiming to state their innovation strategies in an everyday-changing regulatory context. In front of an increased competition of the sector, it will particularly emphasize the Blue Ocean Strategy, a winning option offered to bio-entrpreneurs

Manfred HORST, Director Scientific Liaison, MSD
Bernard GILLY, FOVEA PHARMACEUTICALS
David SOURDIVE, Executive Director, CELLECTIS

Workshop 2: Financing innovation
Which financial strategies for the healthcare bioindustry?

Financing innovation requires a throng of methods, involving both public and private actors.However,it seems crucial–and it is the objective of this workshop–to evaluate the financing opportunities (how they function, their priorities)and to limit the risks for the bio-entrepreneur.

Pierre-Noel LIRSAC, Public Financing Director, LFB
Pierre-Emmanuel AUBERT, President, ANGELS SANTE
Laurent ARTHAUD, Executive Director, CDC Entreprises

Workshop 3: Managing innovation Stakes, challenges and prospects of bio-companies

The management of innovation targets different aspects of the B to B synergy (biotech/biotech and biotech/pharma). This workshop will also show how these synergies canl eadt o efficient and double-winning tech transfer strategies. It will also presen tthe managerial strategies that should be used in order to organise transverse partnerships in a complex socio-economic context.

Patrice DENEFLE, Vice-president, Translational Sciences, IPSEN INNOVATION
Aaron BENSIMON, President, GENOMIC VISION
Bernard MANDRAND, Scientific Director, LYON BIOPOLE

Moderator : Jean-Yves PRAX, POLIA CONSULTING ;

Workshop 4: Marketing innovation
Biotech sector’s specificities

During this workshop, tactical marketing models applied to biotechnology related products will be addressed. Particular attention will be paid to the strategic solutions that may be designed to fully and durably preserve innovation’s competitive advantage. Moreover, the importance of specific and distinctive promotional tools for the biotechnology products will be highlighted.

Jean HACHE, Biotech Field Manager, ESIEE MANAGEMENT
Els VANHEUSDEN,Senior Investment Manager, CAPRICORN VENTURE PARTNERS